US Bancorp DE purchased a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 3,612 shares of the company’s stock, valued at approximately $50,000.
A number of other hedge funds and other institutional investors have also modified their holdings of the company. Rhumbline Advisers raised its holdings in shares of Tyra Biosciences by 4.1% in the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company’s stock valued at $364,000 after purchasing an additional 1,027 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Tyra Biosciences by 5.2% in the 4th quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company’s stock valued at $626,000 after acquiring an additional 2,221 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Tyra Biosciences by 2.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock worth $4,085,000 after acquiring an additional 3,792 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Tyra Biosciences by 1.1% during the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company’s stock worth $8,667,000 after purchasing an additional 3,896 shares during the last quarter. Finally, Ally Bridge Group NY LLC lifted its stake in Tyra Biosciences by 2.0% during the third quarter. Ally Bridge Group NY LLC now owns 270,075 shares of the company’s stock worth $6,349,000 after purchasing an additional 5,415 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, Director Nina S. Kjellson sold 5,401 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the sale, the director now directly owns 443,885 shares of the company’s stock, valued at approximately $6,107,857.60. The trade was a 1.20 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last three months, insiders sold 21,998 shares of company stock valued at $344,818. Insiders own 15.40% of the company’s stock.
Tyra Biosciences Stock Performance
Wall Street Analysts Forecast Growth
Several brokerages have commented on TYRA. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Tuesday, February 18th. UBS Group initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $30.50.
Read Our Latest Report on TYRA
Tyra Biosciences Profile
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Further Reading
- Five stocks we like better than Tyra Biosciences
- Insider Trading – What You Need to Know
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Investing In Preferred Stock vs. Common Stock
- 3 Must-Own Stocks to Build Wealth This Decade
- What is the Euro STOXX 50 Index?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Want to see what other hedge funds are holding TYRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report).
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.